Par Health (planned spin‑off)
Is this your company? Claim this profile
Drug Product
Excipients & Specialty Ingredients
Drug Substance
Company Overview
About
Par Health was a planned spin-off from Mallinckrodt focused on generic pharmaceuticals and sterile injectables. The associated website (mnk-endo.com) now redirects to Keenova, a purpose-driven therapeutics company treating rare and unaddressed conditions in immunology, urology, dermatology, and neurology. This is a branded pharmaceutical company with internal manufacturing, not a contract manufacturer.
Key Expertise
specialty therapeutics, rare disease treatments, generic pharmaceuticals, sterile injectables
Quick Facts
HQ:United States
Capabilities & Services
Markets Served
North America
Manufacturing Facilities
1 site worldwide
Par Health (planned spin‑off) - United States Facility
United States
Site Capabilities
3 capabilitiesGene Therapy
Cell Therapy
mRNA
Certifications
FDA Registration
U.S. Food and Drug Administration